Global Metastatic Bone Pain Market - 2024-2031
Global Metastatic Bone Pain Market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing at a CAGR of XX% during the forecast period 2024-2031.
Pain is the most common symptom of bone metastases. It tends to be a constant, aching pain that may be worse during activity and can cause sleeping difficulties. Bone pain from cancer tends to be quite different from the pain caused by common conditions such as arthritis or muscular strains.
Market Dynamics: Drivers & Restraints
Rise in the prevalence of Cancers
As cancer prevalence increases globally, so does the incidence of bone metastases. Cancers such as breast, prostate, and lung frequently metastasize to bones, leading to a growing need for effective pain management solutions. For instance, the American Cancer Society in 2023, the US experienced 1,958,310 new cancer cases and 609,820 deaths, as per the data from central cancer registries and the National Center for Health Statistics, based on population-based cancer occurrence and outcomes.
Complications associated with the drugs
Metastatic bone pain treatments like opioids and radiation therapy have significant side effects, including addiction, tolerance, and health complications. Radiation therapy can cause skin reactions, fatigue, and systemic effects. Surgical interventions, while beneficial in some cases, carry risks of infections, blood loss, and long recovery times.
Segment Analysis
The global metastatic bone pain market is segmented based on drug type, route of administration, end-user and region.
The NSAIDs from the drug type segment accounted for approximately 47.3%. of the metastatic bone pain market share
The NSAIDs from the drug type segment accounted for approximately 47.3%. Non-steroidal anti-inflammatory drugs since long are in use for the treatment of pain control for all the diseases. They also have an anti-inflammatory effect that makes them an ideal drug for the inflammation caused by certain cancer types during extensive tissue invasion and destruction. A Cochrane review by McNicol and colleagues found that NSAIDs appear to be more effective than placebo for cancer pain.
Geographical Analysis
North America is estimated to hold about 38.4% of the total market share throughout the forecast period
North America is estimated to hold about 38.4% of the total market share throughout the forecast period owing to factors like novel product launches, ongoing clinical trials, FDA approvals, advanced healthcare infrastructure in the region, collaborations and partnerships and others help the region to grow during the forecast period.
For instance, in May 2024, the American Society for Radiation Oncology (ASTRO) outlined recommendations on best practices for treating patients with symptomatic bone metastases and strategies to improve their quality of life, according to updated clinical guidelines published by Alcorn et al in Practical Radiation Oncology.
• Radiation therapy was strongly recommended to manage pain and other symptoms of bone or spine metastases, including those causing compression of the spinal cord or cauda equina.
• Surgery and dexamethasone combined with radiation therapy were recommended over radiation therapy alone in patients with spine metastases causing spinal cord or cauda equina compression. Postoperative radiation therapy was recommended in patients with non-spine bone metastases requiring surgery.
Market Segmentation
By Drug Type
• Non-steroidal Anti-inflammatory Drugs
• Opioids
• Bisphosphonates
• Corticosteroids
• Others
By Route of Administration
• Oral
• Injectable
• Transdermal
By End User
• Hospitals
• Specialty Clinics
• Home Care Settings
• Ambulatory Surgical Centers
• Others
By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Amgen Inc., Novartis AG, Bayer AG, Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Fresenius Kabi, Stryker Corporation, Medtronic plc, Eli Lilly and Company among others.
Why Purchase the Report?
• To visualize the global metastatic bone pain market segmentation based on drug type, route of administration, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the metastatic bone pain market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global metastatic bone pain market report would provide approximately 64 tables, 61 figures, and 186 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
- 1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
- 2. Definition and Overview
- 3. Executive Summary
- 3.1. Snippet by Drug Type
- 3.2. Snippet by Route of Administration
- 3.3. Snippet by End User
- 3.4. Snippet by Region
- 4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Rise in the prevalence of Cancers
- 4.1.1.2. Rise of advancements in treatment options
- 4.1.2. Restraints
- 4.1.2.1. Complications associated with the drugs
- 4.1.2.2. XX
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis
- 5. Industry Analysis
- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Patent Analysis
- 5.6. PESTLE Analysis
- 5.7. SWOT Analysis
- 5.8. DMI Opinion
- 6. By Drug Type
- 6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 6.1.2. Market Attractiveness Index, By Drug Type
- 6.2. Non-steroidal Anti-inflammatory Drugs*
- 6.2.1. Introduction
- 6.3. Opioids
- 6.4. Bisphosphonates
- 6.5. Corticosteroids
- 6.6. Others
- 7. By Route of Administration
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 7.1.2. Market Attractiveness Index, By Route of Administration
- 7.2. Oral*
- 7.2.1. Introduction
- 7.3. Injectable
- 7.4. Transdermal
- 8. By End User
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 8.1.2. Market Attractiveness Index, By End User
- 8.2. Hospitals*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Specialty Clinics
- 8.4. Home Care Settings
- 8.5. Ambulatory Surgical Centers
- 8.6. Others
- 9. By Region
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
- 9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.2.6.1. U.S.
- 9.2.6.2. Canada
- 9.2.6.3. Mexico
- 9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.3.6.1. Germany
- 9.3.6.2. UK
- 9.3.6.3. France
- 9.3.6.4. Italy
- 9.3.6.5. Spain
- 9.3.6.6. Rest of Europe
- 9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.4.6.1. Brazil
- 9.4.6.2. Argentina
- 9.4.6.3. Rest of South America
- 9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 9.5.6.1. China
- 9.5.6.2. India
- 9.5.6.3. Japan
- 9.5.6.4. South Korea
- 9.5.6.5. Rest of Asia-Pacific
- 9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10. Competitive Landscape
- 10.1. Competitive Scenario
- 10.2. Market Positioning/Share Analysis
- 10.3. Mergers and Acquisitions Analysis
- 11. Company Profiles
- 11.1. Amgen Inc *
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
- 11.2. Novartis AG
- 11.3. Bayer AG
- 11.4. Pfizer Inc
- 11.5. Merck & Co Inc
- 11.6. AbbVie Inc
- 11.7. Fresenius Kabi
- 11.8. Stryker Corporation
- 11.9. Medtronic plc
- 11.10. Eli Lilly and Company
- LIST NOT EXHAUSTIVE
- 12. Appendix
- 12.1. About Us and Services
- 12.2. Contact Us
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook